Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

被引：1
|
作者：
Shah, Jatin J. [1 ]
Feng, Lei [1 ]
Manasanch, Elisabet E. [1 ]
Weber, Donna M. [1 ]
Thomas, Sheeba K. [1 ]
Turturro, Francesco [1 ]
Alexanian, Raymond [1 ]
Shah, Nina [1 ]
Popat, Uday R. [1 ]
Nieto, Yago [1 ]
Bashir, Qaiser [1 ]
Qazilbash, Muzaffar H. [1 ]
Champlin, Richard E. [2 ]
Orlowski, Robert Z. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Bortezomib-Dexamethasone vs Bortezomib-Dexamethasone and chemotherapeutic agents in Transplant-Eligible Newly Diagnosed Myeloma
    Abril, Laura
    Pena, Marta
    Ibarra, Gladys
    Gassiot, Susanna
    Oriol, Albert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E215 - E215
  • [42] Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
    Roussel, Murielle
    Hebraud, Benjamin
    Hulin, Cyrille
    Perrot, Aurore
    Caillot, Denis
    Stoppa, Anne-Marie
    Macro, Margaret
    Escoffre, Martine
    Arnulf, Bertrand
    Belhadj, Karim
    Karlin, Lionel
    Garderet, Laurent
    Facon, Thierry
    Guo, Shien
    Weng, Josh
    Dhanasiri, Sujith
    Leleu, Xavier
    Moreau, Philippe
    Attal, Michel
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1323 - 1333
  • [43] Real-World Data on the Daratumumab Plus Bortezomib, Thalidomide and Dexamethasone Followed by Lenalidomide Maintenance for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
    Crusoe, Edvan de Queiroz
    Ribeiro, Glaciano
    Moura, Fernanda
    Costa, Abel
    Aranha, Milton
    Bittencourt, Rosane
    Ribeiro, Eduardo
    Neto, Jorge
    Cunha, Rafael
    Mattos, Ederson
    Braga, Walter
    Lima, Juliana Souza
    Gusmao, Breno
    Lopes, Danielle Ovigli
    Berg, Luiza
    Souto, Joao
    Maiolino, Angelo
    Hungria, Vania T. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S223 - S223
  • [44] Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups
    Chari, Ajai
    Kaufman, Jonathan L.
    Laubach, Jacob P.
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Silbermann, Rebecca
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Bumma, Naresh
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas S.
    Richardson, Paul G.
    Usmani, Saad
    Voorhees, Peter M.
    BLOOD, 2022, 140 : 7278 - 7281
  • [45] Correction to: Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
    Yvette N. Lamb
    Drugs, 2021, 81 : 183 - 183
  • [46] Reduction in disease symptoms/impacts after daratumumab, lenalidomide, bortezomib, and dexamethasone treatment for transplant-eligible patients with newly diagnosed multiple myeloma (GRIFFIN study)
    Silbermann, Rebecca
    Laubach, Jacob
    Kaufman, Jonathan
    Sborov, Douglas
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Costa, Luciano
    Anderson, Larry
    Nathwani, Nitya
    Shah, Nina
    Bumma, Naresh
    Costello, Caitlin
    Jakubowiak, Andrzej
    Orlowski, Robert
    Shain, Ken
    Gries, Katharine
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Matt, Kathryn
    Lin, Thomas
    Usmani, Saad
    Voorhees, Peter
    Richardson, Paul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S125 - S126
  • [47] A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
    O'Donnell, Elizabeth K.
    Laubach, Jacob P.
    Yee, Andrew J.
    Huff, Carol A.
    Basile, Frank G.
    Wade, Philip M., Jr.
    Paba-Prada, Claudia E.
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Couture, Nicole R.
    Doherty, Lauren
    Lyons, Hannah
    English, Caroline
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Richardson, Paul C.
    Raje, Noopur S.
    BLOOD, 2015, 126 (23)
  • [48] Depth of Response to Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Improves Over Time in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma: Griffin Study Update
    Voorhees, Peter M.
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    De Boer, Carla
    Hoehn, Daniela
    Lin, Thomas S.
    Richardson, Paul G.
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 127 - 128
  • [49] A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
    Figueiredo, Amarilis
    Atkins, Harold
    Mallick, Ranjeeta
    Kekre, Natasha
    Kew, Andrea
    McCurdy, Arleigh
    BLOOD, 2016, 128 (22)
  • [50] Treatment of transplant-eligible patients with newly diagnosed multiple myeloma
    Nakaseko, Chiaki
    ANNALS OF ONCOLOGY, 2017, 28
12345